These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

116 related items for PubMed ID: 17692029

  • 1. A comparison of physicochemical property profiles of marketed oral drugs and orally bioavailable anti-cancer protein kinase inhibitors in clinical development.
    Gill AL, Verdonk M, Boyle RG, Taylor R.
    Curr Top Med Chem; 2007; 7(14):1408-22. PubMed ID: 17692029
    [Abstract] [Full Text] [Related]

  • 2. A comparison of physiochemical property profiles of development and marketed oral drugs.
    Wenlock MC, Austin RP, Barton P, Davis AM, Leeson PD.
    J Med Chem; 2003 Mar 27; 46(7):1250-6. PubMed ID: 12646035
    [Abstract] [Full Text] [Related]

  • 3. Molecular inflation, attrition and the rule of five.
    Leeson PD.
    Adv Drug Deliv Rev; 2016 Jun 01; 101():22-33. PubMed ID: 26836397
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. The evolution of synthetic oral drug properties.
    Proudfoot JR.
    Bioorg Med Chem Lett; 2005 Feb 15; 15(4):1087-90. PubMed ID: 15686918
    [Abstract] [Full Text] [Related]

  • 7. 2,4-Diaminopyrimidine inhibitors of c-Met kinase bearing benzoxazepine anilines.
    Zificsak CA, Theroff JP, Aimone LD, Albom MS, Angeles TS, Brown RA, Galinis D, Grobelny JV, Herbertz T, Husten J, Kocsis LS, LoSardo C, Miknyoczki SJ, Murthy S, Rolon-Steele D, Underiner TL, Wells-Knecht KJ, Worrell CS, Zeigler KS, Dorsey BD.
    Bioorg Med Chem Lett; 2011 Jan 15; 21(2):660-3. PubMed ID: 21190849
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Development of specific "drug-like property" rules for carboxylate-containing oral drug candidates.
    Böcker A, Bonneau PR, Hucke O, Jakalian A, Edwards PJ.
    ChemMedChem; 2010 Dec 03; 5(12):2102-13. PubMed ID: 20979082
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. In vitro dissolution methodology, mini-Gastrointestinal Simulator (mGIS), predicts better in vivo dissolution of a weak base drug, dasatinib.
    Tsume Y, Takeuchi S, Matsui K, Amidon GE, Amidon GL.
    Eur J Pharm Sci; 2015 Aug 30; 76():203-12. PubMed ID: 25978875
    [Abstract] [Full Text] [Related]

  • 14. Discovery of 4-(4-aminopyrazolo[1,5-a][1,3,5]triazin-8-yl)benzamides as novel, highly potent and selective, orally bioavailable inhibitors of Tyrosine Threonine Kinase, TTK.
    Laufer R, Li SW, Liu Y, Ng G, Lang Y, Feher M, Brokx R, Beletskaya I, Hodgson R, Mao G, Plotnikova O, Awrey DE, Mason JM, Wei X, Lin DC, Che Y, Kiarash R, Madeira B, Fletcher GC, Mak TW, Bray MR, Pauls HW.
    Bioorg Med Chem Lett; 2016 Aug 01; 26(15):3562-6. PubMed ID: 27335255
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Two Decades under the Influence of the Rule of Five and the Changing Properties of Approved Oral Drugs.
    Shultz MD.
    J Med Chem; 2019 Feb 28; 62(4):1701-1714. PubMed ID: 30212196
    [Abstract] [Full Text] [Related]

  • 18. Relative bioavailability of a prototype oral solution of the Aurora A kinase inhibitor alisertib (MLN8237) in patients with advanced solid tumors.
    Falchook GS, Venkatakrishnan K, Sarantopoulos J, Kurzrock R, Mita AC, Fu S, Mita MM, Zhou X, Jung JA, Ullmann CD, Milch C, Rosen LS.
    Int J Clin Pharmacol Ther; 2015 Jul 28; 53(7):563-72. PubMed ID: 26073352
    [Abstract] [Full Text] [Related]

  • 19. The discovery of Polo-like kinase 4 inhibitors: identification of (1R,2S).2-(3-((E).4-(((cis).2,6-dimethylmorpholino)methyl)styryl). 1H.indazol-6-yl)-5'-methoxyspiro[cyclopropane-1,3'-indolin]-2'-one (CFI-400945) as a potent, orally active antitumor agent.
    Sampson PB, Liu Y, Forrest B, Cumming G, Li SW, Patel NK, Edwards L, Laufer R, Feher M, Ban F, Awrey DE, Mao G, Plotnikova O, Hodgson R, Beletskaya I, Mason JM, Luo X, Nadeem V, Wei X, Kiarash R, Madeira B, Huang P, Mak TW, Pan G, Pauls HW.
    J Med Chem; 2015 Jan 08; 58(1):147-69. PubMed ID: 25723005
    [Abstract] [Full Text] [Related]

  • 20. Novel tetracyclic benzo[b]carbazolones as highly potent and orally bioavailable ALK inhibitors: design, synthesis, and structure-activity relationship study.
    Jiang X, Zhou J, Ai J, Song Z, Peng X, Xing L, Xi Y, Guo J, Yao Q, Ding J, Geng M, Zhang A.
    Eur J Med Chem; 2015 Nov 13; 105():39-56. PubMed ID: 26476749
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 6.